Novavax, Inc. (NVAX)
Novavax is a biotechnology company that develops vaccines to protect against infectious diseases like COVID-19 and seasonal flu.
Is Novavax, Inc. a good stock for a UK beginner?
The honest version: There's no rating here and nothing for sale. In its favour: Specialised expertise in protein-based vaccine technology. Worth weighing: Significant decline in recent revenue. Below, we lay out what it does, what its numbers mean, and the honest risks, so you can decide for yourself.
Over about 2 years to 2026-07-31. This is the share price only; any dividends would add to it. And it's the USD return - as a UK investor your actual £ return also moves with the exchange rate. Past performance is not a guide to the future, and it could just as easily have fallen.
How much has Novavax, Inc. actually fallen?
Over the last 2 years of daily prices, Novavax, Inc. fell as much as −63% from a high to a later low. Drops of this size are a normal part of owning a share - worth knowing in advance, so a dip doesn't come as a shock.
Worst peak-to-trough fall in the daily closing price over the period we hold. Past falls are not a forecast - it can fall further, or recover.
Based on beta - how much the price swings versus the whole market. Bumpier isn't bad; it just means a rougher ride, which matters more the sooner you might need the money.
Prices move on results, news and the mood of the whole market - no single headline explains a day, and a quiet week is usually just noise, not a signal.
The company establishes itself as a reliable player in the seasonal vaccine market.
The company runs out of cash or fails to compete with larger pharmaceutical rivals.
What does Novavax, Inc. do?
Novavax focuses on creating vaccines using a unique protein-based technology that helps the body recognise and fight off viruses. Revenue comes from supplying these vaccines to governments and health organisations around the world. How smoothly they pivot from their pandemic-era products to their new, combined flu and COVID-19 vaccine candidates is what really matters here.
On our factor screen it looks strongest on value and momentum, and weakest on growth.
- !Pays no dividend - the whole return rides on the share price
- !Revenue slipped about 79% over the year
- Value screens high (77/100)
- Specialised expertise in protein-based vaccine technology
- Potential for a combined flu and COVID-19 vaccine
- Established infrastructure for vaccine manufacturing
- Quality screens low (14/100)
- Growth screens low (0/100)
- Momentum screens low (20/100)
- Income screens low (16/100)
- Heavy reliance on a small number of products
What do Novavax, Inc.'s numbers mean?
How much money does Novavax, Inc. make?
Revenue and profit by quarter, and how much of each sale turns into profit.
Does Novavax, Inc. pay a dividend?
No - Novavax, Inc. doesn't currently pay a dividend, so the whole return would rest on the share price. Plenty of growing companies reinvest their profits instead of paying them out - neither approach is better or worse, they're just different.
When does Novavax, Inc. report earnings, and how did recent quarters go?
Novavax, Inc. is next scheduled to report on about 2026-08-06 - dates can move, and we don't predict results; this just tells you when to look.
Each quarter a company reports its results against what analysts expected. ‘Beating’ or ‘missing’ is about that expectation, not whether the business is doing well in absolute terms.
| Reported | Expected EPS: The earnings per share analysts expected for the quarter - the average of their forecasts. 'Beating' or 'missing' is measured against this number. | Actual EPS | vs expected |
|---|---|---|---|
| 2026-05-06 | $-0.37 | $-0.06 | Beat +84% |
| 2026-02-26 | $-0.55 | $0.11 | Beat +120% |
| 2025-11-06 | $-1.13 | $-0.47 | Beat +58% |
| 2025-08-06 | $0.06 | $0.62 | Beat +1000% |
| 2025-05-08 | $0.71 | $2.93 | Beat +314% |
| 2025-02-27 | $-0.51 | $-0.52 | Missed -1% |
Across the last 6 quarters here, Novavax, Inc. came in ahead of what analysts expected 5 times. One quarter is noise, not a trend.
See who else reports over the next two weeks →
Reported vs expected earnings per share (EPS) from published results; the expectation is the analyst consensus, not our view. Report dates are estimates that can move.
More in Healthcare
Eli Lilly
West Pharmaceutical Services, Inc.
Incyte Corporation
The Cigna Group
Zimmer Biomet Holdings, Inc.
Moderna, Inc.
Gilead Sciences, Inc.
Regeneron Pharmaceuticals, Inc.What are the scenarios for Novavax, Inc.?
An illustrative range for the year ahead, with the assumption behind each case — not a prediction or a price target.
What are the pros and cons of Novavax, Inc.?
How many points the write-up makes each way — a balance check, not a score or verdict.
- Specialised expertise in protein-based vaccine technology
- Potential for a combined flu and COVID-19 vaccine
- Established infrastructure for vaccine manufacturing
- Significant decline in recent revenue
- Currently operating at a loss
- High share price volatility
- Heavy reliance on a small number of products
- Intense competition from much larger pharmaceutical companies
- Uncertainty regarding future government vaccine procurement
The write-up's own warning lights — if these start happening, the case above changes.
- The company achieving consistent quarterly profitability
- A major partnership or buyout by a larger pharmaceutical firm
Built from public filings & market prices, checked for an education-only tone, and never a price target. How we make these →
This plain-English summary was auto-generated on 2026-08-02 from public data and checked for an education-only, no-advice tone (the figures above carry their own, usually fresher, 'as of' date). It's information, never a recommendation.